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Background:  Clopidogrel is an important antiplatelet drug for the prevention of stent thrombosis after percutaneous coronary intervention (PCI). 
This drug requires transformation into an active metabolite by CYP2C19 for antiplatelet effect. However, CYP2C19 *2 and *3 polymorphisms known 
to lack enzymatic activity are considered to reduce antiplatelet effect of clopidogrel.
Methods:  We assessed the association between polymorphisms of CYP2C19 *2 and *3, and platelet reactivity after clopidogrel measured by 
the VerifyNow-P2Y12 assay in 29 consecutive patients with coronary artery disease undergoing PCI. All patients received dual antiplatelet therapy 
under 100mg aspirin therapy, 300mg clopidogrel was loaded on the 1st day and a daily 75mg dose was administered on the following days. Blood 
samples for the VerifyNow-P2Y12 assay were obtained beyond 24 hours after dual antiplatelet therapy administration.
Results:  On the basis of CYP2C19 genotype, 13 patients (44%) were classified as extensive metabolizers (EMs), 9 patients (31%) as intermediate 
metabolizers [IMs; 7 (24%) patients were CYP2C19*2 heterozygotes (*1/*2), and 2 (6.9%) CYP2C19*3 heterozygotes (*1/*3)], and 7 patients 
(24%) as poor metabolizers [PMs; 3 (10%) patients were CYP2C19*2 homozygotes (*2/*2), 2 (6.9%) CYP2C19*3 homozygotes (*3/*3), and 
2 (6.9%) both CYP2C19*2 and CYP2C19*3 mutant alleles (*2/*3)]. Twelve (41%) patients carried the CYP2C19*2 allele, and 6 (21%) the 
CYP2C19*3 allele. Platelet reactivity in PMs was significantly higher than that in EMs [349.0 ± 43.6 VS 238.1 ± 93.9 P2Y12 reaction units (PRU), 
p=0.009], and was also significantly higher than that in IMs (349.0 ± 43.6 VS 253.9 ± 78.7 PRU, p=0.01)
Conclusions:  CYP2C19 polymorphisms are frequent in Japanese patients and the rates of carriers of the CYP2C19*2 and *3 allele were 41% and 
21%. Platelet reactivity after clopidogrel is reduced by CYP2C19 polymorphisms.
